A Randomized, Open-label Study of the Effect of Paclitaxel, Doxorubicin, and CMF Neoadjuvant Chemotherapy, With and Without Herceptin, on Tumor Response in Women With HER2-positive Breast Cancer
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Trastuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Fluorouracil; Methotrexate; Paclitaxel
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Sponsors Roche
- 05 Dec 2013 New source identified and integrated: ClinicalTrials.gov record.
- 16 Jun 2006 New trial record.